Prior randomized controlled trials have been conducted with TNF-alpha blockers, including certolizumab pegol and adalimumab, to treat patients with severe refractory IC/BPS (Bosch, 2018; Bosch, 2014). Here, TNF is linked to Bartsocas-Papas syndrome 1.